ஐ.எஸ்.எஸ்.என்: 2161-0398
Andrei M Balas, Francis P Gasparro*
Psoralens have been used in the treatment of several skin diseases such as psoriasis and atopic eczema through PUVA (Psoralen+UVA), cutaneous T-cell lymphoma through ECP (Extracorporeal Photochemotherapy), and recently, the treatment of solid tumors through X-PACT (X-ray Psoralen Activated Cancer Therapy). The flat-planar psoralens intercalate or slide in-between base pairs and when exposed to UVA, form photo-adducts with the DNA backbone which can stop or slow DNA replication. The intrinsic ability of psoralens to bind with DNA and their therapeutic effectiveness contribute to the increased interest in the study of these molecules. Several studies measuring psoralen- DNA binding capabilities have used a variety of spectroscopic techniques and different experimental conditions. In this study, spectrofluorometry was used to measure the DNA-binding capabilities of three different psoralen derivatives (6E, AMT and 8-MOP) under identical experimental conditions. The binding constants were 0.325 × 106 M-1 for 8-MOP, 0.516 × 106 M-1 for AMT, and 7.30 × 106 M-1 for 6E. This direct comparison of the three different psoralens demonstrated the impact of their molecular structure on the DNA-binding capacity. 6E’s significantly greater binding constant makes it the stronger candidate for further studies looking into potential applications for cancer treatment.